• 1
    Sandberg AA: The Chromosomes in Human Cancer and Leukemia, ed 2. New York, Elsevier Science Publishing Co., 1990.
  • 2
    Le Beau MM: Cytogenetic analysis of hematological malignant diseases, in BarchMJ (ed): The ACT Cytogenetics Laboratory Manual, ed 2. New York, Raven Press, 1991, pp. 395445.
  • 3
    Sandberg AA, Bridge JA: The Cytogenetics of Bone and Soft-Tissue Tumors. Austin, Tex, R.G. Landes Co., 1994.
  • 4
    Heim S, Mitelman F: Cancer Cytogenetics. New York, Alan R. Liss, Inc., 1987.
  • 5
    Rowley JD, Aster JC, Sklar J: The clinical applications of new DNA diagnostic technology on the management of cancer patients. JAMA 1993; 270: 23312337.
  • 6
    Rowley JD, Aster JC, Sklar J: The impact of new DNA diagnostic technology on the management of cancer patients. Arch Pathol Lab Med 1993; 117: 11041109.
  • 7
    Sandberg AA: Chromosomes and leukemia. CA 1965; 15: 213, 42–44.
  • 8
    Sandberg AA, Yamada K: Chromosomes and cancer. CA 1965; 15: 5874.
  • 9
    Knudson AG: Antioncogenes and human cancer. Proc Natl Acad Sci U S A 1993; 90: 1091410921.
  • 10
    Buja LM, Eigenbrodt ML, Eigenbrodt EH: Apoptosis and necrosis: Basic types and mechanisms of cell death. Arch Pathol Lab Med 1993; 117: 12081214.
  • 11
    Williams GT, Smith CA: Molecular regulation of apoptosis: Genetic controls on cell death. Cell 1993; 74: 777779.
  • 12
    Carson DA, Ribeiro JM: Apoptosis and disease. Lancet 1993; 341: 12511254.
  • 13
    Sandberg AA, Bridge JA: Techniques in cancer cytogenetics: An overview and update. Cancer Invest 1992; 10: 163172.
  • 14
    Chen Z, Morgan R, Berger CS, Sandberg AA: Application of fluorescence in situ hybridization in hematological disorders. Cancer Genet Cytogenet 1992; 63: 6269.
  • 15
    Wessman M, Popp S, Ruutu T, et al: Detection of residual host cells after bone marrow transplantation using non-isotopic in situ hybridization and karyotype analysis. Bone Marrow Transplant 1993; 11: 279284.
  • 16
    Chen Z, Morgan R, Stone JF, Sandberg AA: FISH: A useful technique in the verification of clonality of random chromosome abnormalities. Cancer Genet Cytogenet 1993; 66: 7374.
  • 17
    Meloni AM, Peier AM, Haddad FS, et al: A new approach in the diagnosis and follow-up of bladder cancer: FISH analysis of urine, bladder washings, and tumors. Cancer Genet Cytogenet 1993; 71: 105118.
  • 18
    Borden EC, Waalen J, Liberati AM, Grignani F: Molecular diagnosis and monitoring of leukemia and lymphoma. Leuk Res 1993; 17: 10731078.
  • 19
    Miller Jr WH, Levine K, DeBlasio A, et al: Detection of minimal residual disease in acute promyelocytic leukemia by a reverse transcription polymerase chain reaction assay for the PML/RAR- fusion mRNA. Blood 1993; 82: 16891694.
  • 20
    Potter MN, Cross NC, van Dongen JJ, et al: Molecular evidence of minimal residual disease after treatment for leukaemia and lymphoma: an updated meeting report and review. Leukemia 1993; 7: 13021314.
  • 21
    de Thé H, Chomienne C, Lanotte M, et al: The t(15;17) translocation of acute promyelocytic leukemia fuses the retinoic acid receptor gene to a novel transcribed locus. Nature 1990; 347: 558561.
  • 22
    Chen Z, Morgan R, Berger CS, et al: Identification of masked and variant Ph (complex type) translocations in CML and classic Ph in AML and ALL by fluorescence in situ hybridization with the use of bcr/abl cosmid probes. Cancer Genet Cytogenet 1993; 70: 103107.
  • 23
    Schneider NR: Cytogenetic evaluation of childhood neoplasms. Arch Pathol Lab Med 1993; 117: 12201224.
  • 24
    Sandberg AA, Wullich B: Myelodysplastic syndromes: Cytogenetic anomalies and their clinical significance, in SchmalzlF, MuftiGJ (eds): Myelodysplastic Syndromes. New York, Springer-Verlag, 1992, pp 165177.
  • 25
    Nowell P: Chromosome abnormalities in myelodysplastic syndromes. Semin Oncol 1992; 19: 2533.
  • 26
    List AF, Garewal HS, Sandberg AA: The myelodysplastic syndromes: Biology and implications for management. J Clin Oncol 1990; 8: 14241441.
  • 27
    Cogswell PC, Morgan R, Dunn M, et al: Mutations of the ras protooncogenes in chronic myelogenous leukemia: A high frequency of ras mutations in bcrlabl rearrangement-negative chronic myelogenous leukemia. Blood 1989; 74: 26292633.
  • 28
    Gaidano G, Guerrasio A, Serra A, et al: Mutations in the p53 and RAS family genes are associated with tumor progression of BCR/ABL negative chronic myeloproliferative disorders. Leukemia 1993; 7: 946953.
  • 29
    Paquette RL, Landaw EM, Pierre RV, et al: N-ras mutations are associated with poor prognosis and increased risk of leukemia in myelodysplastic syndrome. Blood 1993; 82: 590599.
  • 30
    Willman CL, Sever CE, Pallavicini MG, et al: Deletion of IRF-1, mapping to chromosome 5q31.1, in human leukemia and preleukemic myelodysplasia. Science 1993; 259: 968971.
  • 31
    Döhner H, Pohl S, Bulgay-Mörschel M, et al: Trisomy 12 in chronic lymphoid leukemias: A metaphase and interphase cytogenetic analysis. Leukemia 1993; 7: 516520.
  • 32
    Escudier SM, Pereira-Leahy JM, Drach JW, et al: Fluorescent in situ hybridization and cytogenetic studies of trisomy 12 in chronic lymphocytic leukemia. Blood 1993; 81: 27022707.
  • 33
    Que TH, Marco JG, Ellis J, et al: Trisomy 12 in chronic lymphocytic leukemia detected by fluorescence in situ hybridization: Analysis by stage, immunophenotype, and morphology. Blood 1993; 82: 571575.
  • 34
    Newman RA, Peterson B, Davey FR, et al: Phenotypic markers and BCL-1 gene rearrangements in B-cell chronic lymphocytic leukemia: A Cancer and Leukemia Group B study. Blood 1993; 82: 12391246.
  • 35
    Foon KA, Gale RP: Is there a T-cell form of chronic lymphocytic leukemia? Leukemia 1992; 6: 867868.
  • 36
    Offit K, Parsa NZ, Gaidano G, et al: 6q deletions define distinct clinico-pathologic subsets of non-Hodgkin's lymphoma. Blood 1993; 82: 21572162.
  • 37
    Gupta RK, Whelan JS, Lister TA, et al: Direct sequence analysis of the t(14;18) chromosomal translocation in Hodgkin's disease. Blood 1992; 79: 20842088.
  • 38
    Lambrechts AC, Hupkes PE, Dorssers LC, van't Veer MB: Translocation (14;18)-positive cells are present in the circulation of the majority of patients with localized (stage I and II) follicular non-Hodgkin's lymphoma. Blood 1993; 82: 25102516.
  • 39
    Aisenberg AC: Utility of gene rearrangements in lymphoid malignancies. Annu Rev Med 1993; 44: 7584.
  • 40
    Jaeger U, Purtscher B, Karth GD, et al: Mechanism of the chromosomal translocation t(14;18) in lymphoma: Detection of a 45-Kd breakpoint binding protein. Blood 1993; 81: 18331840.
  • 41
    Sandberg AA: The cytogenetics of solid tumors. Advances in Oncology 1992; 8: 39.
  • 42
    Vogelstein B, Fearon ER, Hamilton SR, et al: Genetic alterations during colorectal-tumor development. N Engl J Med 1988; 319: 525532.